search
Back to results

Insulin Glulisine in Type 2 Diabetic Patients (Basal Plus)

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
Insulin Glargine
Glimepiride
Insulin Glulisine
Metformin
Sponsored by
Sanofi
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Diabetes Mellitus, Type 2 25 < BMI < 45 kg/m² 7,5% < HbA1c < 9% Treated with a basal insulin (NPH, Insulin Zinc, Insulin glargine or Insulin detemir), and at least 1g metformin daily, for more than 3 months Exclusion Criteria: Type 1 diabetes mellitus Treatment with OADs only Treatment with thiazolidinediones, with exenatide or with pramlintide Treatment with an insulin other than basal insulin (Premix, rapid insulin, fast-acting insulin analogue) Active proliferative diabetic retinopathy, Pregnancy (women of childbearing potential must have a negative pregnancy test at study entry and effective contraception) Breast-feeding History of hypersensitivity to the study drugs or to drugs with a similar chemical structure. Treatment with systemic corticosteroids in the 3 months prior to study entry Treatment with any investigational product in the 2 months prior to study entry Previous treatment with insulin glulisine Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major disease making implementation of the protocol or interpretation of the study results difficult Impaired hepatic function Impaired renal function History of drug or alcohol abuse The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Sites / Locations

  • Sanofi-aventis
  • Sanofi-Aventis
  • Sanofi-aventis

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

insulin glulisine+insulin glargine+metformin+glimepiride

insulin glargine+metformin+glimepiride

Arm Description

Bolus arm

Control arm

Outcomes

Primary Outcome Measures

Patients With Glycosylated Haemoglobin (HbA1c) Value < 7%
Glycosylated Haemoglobin (HbA1c) is a biological parameter that reflects the blood glucose concentration over a long period of time. It is the standard parameter for glycemic control follow -up in diabetic patients. this parameter is expressed in percentage (%) and the target in diabetes management is to reach a HbA1c <7%

Secondary Outcome Measures

Glycosylated Haemoglobin (HbA1c) Value
Change in Glycosylated Haemoglobin (HbA1c) Value
Daily Mean Plasma Glucose
Change in Daily Mean Plasma Glucose
Change in Weight
Daily Dose of Insulin Glargine
Mean of 3 daily doses reported during the week prior to the final visit
Daily Dose of Insulin Glulisine
Mean of 3 daily doses reported during the week prior to the final visit
Rate of Symptomatic Hypoglycemia With Plasma Glucose < 70mg/dL
Rate of Nocturnal Symptomatic Hypoglycemia With Plasma Glucose < 70mg/dL
Rate of Severe Symptomatic Hypoglycemia

Full Information

First Posted
August 3, 2006
Last Updated
August 1, 2011
Sponsor
Sanofi
search

1. Study Identification

Unique Protocol Identification Number
NCT00360698
Brief Title
Insulin Glulisine in Type 2 Diabetic Patients
Acronym
Basal Plus
Official Title
Comparison of Two Therapeutic Strategies for Treating Type 2 Diabetic Patients Poorly Controlled With Basal Insulin Associated With Oral Antidiabetic Drugs : 6-month Proof of Concept Study.
Study Type
Interventional

2. Study Status

Record Verification Date
August 2011
Overall Recruitment Status
Completed
Study Start Date
July 2006 (undefined)
Primary Completion Date
August 2008 (Actual)
Study Completion Date
August 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Sanofi

4. Oversight

5. Study Description

Brief Summary
To evaluate the efficacy of a single injection of glulisine before the main meal added to insulin glargine plus oral antidiabetic drugs (OADs) compared to insulin glargine plus OADs in Type 2 diabetic patients poorly controlled with basal insulin plus OADs.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
106 (Actual)

8. Arms, Groups, and Interventions

Arm Title
insulin glulisine+insulin glargine+metformin+glimepiride
Arm Type
Other
Arm Description
Bolus arm
Arm Title
insulin glargine+metformin+glimepiride
Arm Type
Other
Arm Description
Control arm
Intervention Type
Drug
Intervention Name(s)
Insulin Glargine
Intervention Description
One daily injection at bedtime
Intervention Type
Drug
Intervention Name(s)
Glimepiride
Intervention Description
At same dosage as during the run-in period
Intervention Type
Drug
Intervention Name(s)
Insulin Glulisine
Intervention Description
One bolus given before the main meal
Intervention Type
Drug
Intervention Name(s)
Metformin
Intervention Description
At same dosage as during the run-in period
Primary Outcome Measure Information:
Title
Patients With Glycosylated Haemoglobin (HbA1c) Value < 7%
Description
Glycosylated Haemoglobin (HbA1c) is a biological parameter that reflects the blood glucose concentration over a long period of time. It is the standard parameter for glycemic control follow -up in diabetic patients. this parameter is expressed in percentage (%) and the target in diabetes management is to reach a HbA1c <7%
Time Frame
at the end of treatment (week 24)
Secondary Outcome Measure Information:
Title
Glycosylated Haemoglobin (HbA1c) Value
Time Frame
at the end of treatment (week 24)
Title
Change in Glycosylated Haemoglobin (HbA1c) Value
Time Frame
from baseline to the end of treatment (week 24)
Title
Daily Mean Plasma Glucose
Time Frame
at the end of treatment (week 24)
Title
Change in Daily Mean Plasma Glucose
Time Frame
from baseline to the end of treatment (week 24)
Title
Change in Weight
Time Frame
from baseline to the end of treatment (week 24)
Title
Daily Dose of Insulin Glargine
Description
Mean of 3 daily doses reported during the week prior to the final visit
Time Frame
at the end of treatment (week 24)
Title
Daily Dose of Insulin Glulisine
Description
Mean of 3 daily doses reported during the week prior to the final visit
Time Frame
at the end of treatment (week 24)
Title
Rate of Symptomatic Hypoglycemia With Plasma Glucose < 70mg/dL
Time Frame
during treatment period (12 weeks)
Title
Rate of Nocturnal Symptomatic Hypoglycemia With Plasma Glucose < 70mg/dL
Time Frame
during treatment period (12 weeks)
Title
Rate of Severe Symptomatic Hypoglycemia
Time Frame
during treatment period (12 weeks)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diabetes Mellitus, Type 2 25 < BMI < 45 kg/m² 7,5% < HbA1c < 9% Treated with a basal insulin (NPH, Insulin Zinc, Insulin glargine or Insulin detemir), and at least 1g metformin daily, for more than 3 months Exclusion Criteria: Type 1 diabetes mellitus Treatment with OADs only Treatment with thiazolidinediones, with exenatide or with pramlintide Treatment with an insulin other than basal insulin (Premix, rapid insulin, fast-acting insulin analogue) Active proliferative diabetic retinopathy, Pregnancy (women of childbearing potential must have a negative pregnancy test at study entry and effective contraception) Breast-feeding History of hypersensitivity to the study drugs or to drugs with a similar chemical structure. Treatment with systemic corticosteroids in the 3 months prior to study entry Treatment with any investigational product in the 2 months prior to study entry Previous treatment with insulin glulisine Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major disease making implementation of the protocol or interpretation of the study results difficult Impaired hepatic function Impaired renal function History of drug or alcohol abuse The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
PILORGET Valérie, MD
Organizational Affiliation
Sanofi
Official's Role
Study Director
Facility Information:
Facility Name
Sanofi-aventis
City
Bridgewater
State/Province
New Jersey
ZIP/Postal Code
08807
Country
United States
Facility Name
Sanofi-Aventis
City
Moscow
Country
Russian Federation
Facility Name
Sanofi-aventis
City
Guildford
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

Insulin Glulisine in Type 2 Diabetic Patients

We'll reach out to this number within 24 hrs